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Background: Fragile X-associated tremor/ataxia syndrome (FXTAS) is an inherited late-onset neurodegenerative
disorder, characterized both by neurological and cognitive deficits. It is caused by the expansion of CGG repeats (55
to 200 repeats) in the noncoding region of the fragile X mental retardation 1 (FMR1) gene. Abnormal
immunological patterns are often associated with neurodegenerative disorders and implicated in their etiology. We
therefore investigated the immune status of FXTAS patients, which had not been assessed prior to this study.
Method: Peripheral blood mononuclear cells (PBMCs) were collected from 15 asymptomatic FMR1 premutation
carriers and 20 age-matched controls. Concentrations of three cytokines (IL-6, IL-8, IL-10) were measured in PBMC
supernatants using ELISA assays.
Results: We found a significant increase in the concentration of the major anti-inflammatory cytokine IL-10 in
supernatants of PBMCs derived from premutation carriers, when compared with controls (P = 0.019). This increase
correlated significantly with the number of CGG repeats (P = 0.002).
Conclusions: Elevated IL-10 levels were observed in all premutation carriers, before appearance of the classical
neurological symptoms; therefore, IL-10 may be one of the early biomarkers of FXTAS.
Keywords: Fragile X mental retardation 1 (FMR1) gene, Fragile X-associated tremor ataxia syndrome, Immune
activation, Cytokines, IL-10Background
Fragile X-associated tremor/ataxia syndrome (FXTAS
[OMIM:300623]) is a late-onset neurodegenerative dis-
order. FXTAS is caused by the expansion of CGG tri-
plets (55 to 200 repeats) in the 50-UTR of the fragile X
mental retardation 1 (FMR1) gene, termed premutation.
The disease symptoms include: progressive intention
tremor, gait ataxia associated with cognitive decline, per-
ipheral neuropathy, and autonomic dysfunction [1]. In
women, these signs are less frequent and less severe, but
autoimmune dysfunction has been reported [2,3].* Correspondence: goranka.tanackovic@unil.ch
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reproduction in any medium, provided the orFXTAS is a disease with reduced penetrance: ~50% of
male carriers of the FMR1 premutation (prevalence 1 in
~500 men) and a smaller fraction of female carriers will
develop FXTAS [1,4-6]. Therefore it is important to iden-
tify biomarkers that will help monitor disease progression.
At the cellular level, premutation carriers present
increased amounts of expanded FMR1mRNA and a slight
reduction in the encoded protein [7,8]. The expanded
mRNA accumulates within the FXTAS-characteristic
intranuclear inclusions [9], together with at least 30 differ-
ent proteins including ubiquitin, stress response factors,
and cytoskeletal proteins [10]. An RNA toxic gain of func-
tion was proposed as the molecular mechanism under-
lying FXTAS, and it was demonstrated that severity of
both the clinical and the neuropathological phenotypes
correlate positively both with the extent of the CGG-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expanded mRNA [4]. The neuropathology of FXTAS
includes significant white matter disease (spongiosis in the
cerebrum and cerebellum), prominent subcortical astro-
glial activation, Purkinje cell loss and the presence of intra-
nuclear inclusions in neurons and astrocytes throughout
the cortex [1,4]. How this expanded RNA yields the patho-
logical changes observed in patients remains obscure.
Evidence suggests that neuronal loss correlates with
either causal or secondary excessive inflammatory
response [11-14], and neuroinflammation has been
implicated in a broad spectrum of neurodegenerative
disorders such as Parkinson’s disease (PD), Alzheimer’s
disease (AD), amyotrophic lateral sclerosis, Huntington’s
disease (HD), and multiple sclerosis (reviewed in [11]).
Experimental evidence shows that suppression of inflam-
matory processes mitigates neuronal loss in in vivo and
in vitro models of neurodegenerative diseases [15-18].
Importantly, a prolonged use of nonsteroidal anti-
inflammatory drugs was beneficial in both AD and PD
[19-22]. Taken together, these data suggest that uncon-
trolled inflammation, either as an initiator or as a sec-
ondary reaction, could drive chronic and progressive
neurodegenerative processes.
FXTAS is a recently described neurodegenerative dis-
order and almost nothing is known about the immune
status of the patients. We investigated the immune pro-
file of individuals carrying the FMR1 premutation, hav-
ing no apparent neurological symptoms. In particular,
we assessed the profiles of three cytokines in their per-
ipheral blood and compared them with those of age-
matched control individuals. Our results show that
increased levels of IL-10 in peripheral blood are asso-
ciated with the FMR1 premutation. This suggests IL-10
as an early characteristic of FXTAS.
Methods
Participants and study design
All participants signed an informed consent; the study
was reviewed and accepted by the institutional review
board of the University of Lausanne. Initially, we
recruited 38 male individuals: 17 carriers of the FMR1
premutation and 21 age-matched controls. The two
groups of controls and carriers were defined using a cut-
off value of 55 CGG repeats (Additional file 1: Table S1).
Participants (n = 3) who experienced a recent infection
(indicated by increased C-reactive protein levels) were
excluded. Samples from 15 individuals adequate for the
analyses were included in the carrier cohort, while the
control group was composed of 20 individuals.
The following clinical phenotypes were recorded and
scored in both groups (Additional file 1: Table S1): dia-
stolic and systolic blood pressure (DBP and SBP), ab-
sence or presence of diabetes mellitus (0 and 1,respectively), hemoglobin A1c (corresponding to the
percentage of glycated hemoglobin), smoking status, and
treatment status defined as treatment with neuroleptic
or psychotropic drugs and/or drugs intended to prevent
cardiovascular diseases. The structured neurological
examination was videotaped, and included the Unified
Parkinson’s Disease Rating Scale (UPDRS), the Inter-
national Cooperative Ataxia Rating Scale (ICARS), and
the Clinical Rating Scale for Tremor (CRST). The total
score of the FXTAS Rating Scale (combination of
UPDRS, ICARS and CRST scales and the Singer test)
[23] was used as the single clinical score.
Isolation of peripheral blood mononuclear cells
Peripheral blood samples were collected in the presence
of ethylenediamine tetraacetic acid as anticoagulant. Per-
ipheral blood mononuclear cells (PBMCs) were rapidly
isolated (within 2 hours following blood draw). The
Ficoll separation procedure (Ficoll-Paque Plus; GE
Healthcare Life Sciences, Uppsala, Sweden) was used to
separate PBMCs and plasma, according to the manufac-
turer’s instructions. PBMCs were washed three times
with RPMI supplemented with 10% FCS and then cul-
tured in 12-well plates in RPMI with FCS for 24 hours.
Supernatants of the cultures were collected and stored
at −20°C for further analyses.
Measurements of cytokines
Cytokines were measured first in undiluted PBMC
supernatants using a Milliplex MAP kit (HCYTOMAG-
60K; Merck Millipore, Billerica, MA, USA) for the
detection of IL-6, IL-8 and IL-10, according to the man-
ufacturer’s instructions. Data were acquired using a Bio-
Plex 200 instrument (Bio-Rad, Hercules, CA, USA) and
analyzed using Bio-Plex Manager Software (version 4.1;
Bio-Rad). Since the concentration levels of IL-6 and IL-8
were at the higher end of the standard curve, we per-
formed additional measurements to determine their
levels, following the dilution of PBMC supernatants
(1:150), using the ELISA kits Interleukin 6 high sensitiv-
ity human ELISA Set and Interleukin 8 high sensitivity
human ELISA Set (both ImmunoTools, Friesoythe,
Germany), following the manufacturer’s instructions.
Measurements were performed three times for IL-6 and
IL-8 and twice for IL-10.
Statistical analyses
For each recorded characteristic, we computed the mean
and standard deviation or the percentage of occurrence
in both control and premutation carrier groups. We per-
formed different statistical tests in order to assess the
group effect on the set of clinical feature means or med-
ians. For normally distributed continuous variables, such
as age and FXTAS Rating Scale, we ran a one-way
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the F-test P values to determine whether the pheno-
types from the two groups had a common mean or a
different mean at an α level of 5%. DBP and SBP mea-
surements, as well as hemoglobin A1c concentrations,
showed continuous but not normal distributions; we
therefore applied a nonparametric version of one-way
ANOVA, the Kruskal–Wallis test. Chi-square test P <5%
suggests that the control group median is significantly
different from the premutation carrier group. Finally, to
test the group effect on smoking and treatment status, a
generalized linear model for binomial distributions was
applied. The outcomes were restricted to two values,
which represented the occurrence or nonoccurrence of
the event. The test predicts the probability of smoking or
being under treatment as a function of the group (con-
trols or premutation carriers).
Raw cytokine measurements were log-transformed
(natural logarithm) to better satisfy the normality as-
sumption underlying linear regression models and then
averaged. The following analyses were all run on aver-
aged log-transformed cytokine concentrations (stated as
m-IL in figures and tables).
To assess the influence of CGG repeats on cytokine
concentrations, linear regression analyses were per-
formed modeling the cytokine levels as a function of the
number of CGG repeats. A Student's t test and its corre-
sponding P value were therefore computed to test for
the significance of the β regression coefficient associated
with the CGG repeats. The squared correlation coeffi-
cient R2 – which indicates the proportion of variance in
one variable, explained by knowledge of the second vari-
able – was computed. The same analysis was performed
adding the age variable into the model.
Multiple regression analysis was also used to assess
the relationship between the FXTAS rating scale scores
and the following variables: CGG repeats and age of the
patients.
To identify differences in IL-10 mean concentrations
between the premutation carrier and control groups,
means and standard deviations for both groups were
computed and a one-way ANOVA was performed. The
P value for the F-test statistic was computed.
Finally, Pearson's correlations were computed to ex-
plore whether there was a correlation between the
FXTAS rating scale and the cytokine levels.
All statistical analyses were performed using Matlab®
(The MathWorks Inc., Natick, MA, USA).
Results
Clinical assessment of the premutation carriers and
controls
Several clinical and biological phenotypes were mea-
sured and compared between premutation carriers andcontrols (Figure 1A). The number of CGG repeats ran-
ged from 20 to 46 in controls and from 57 to 109 in car-
riers. The two groups did not significantly differ in age:
mean ± standard deviation = 52.20 ± 11.60 and 45.70 ±
11.36 years for the carriers and controls, respectively
(P = 0.11). Neither did the groups differ in the presence
of hypertension (DBP: 83.15 ± 7.12 vs. 78.35 ± 8.95; P =
0.10 and SBP: 124.36 ± 11.74 vs. 120.3 ± 12.74; P =
0.21), presence of diabetes mellitus (hemoglobin A1C:
5.86 ± 1.50 vs. 5.42 ± 0.50; P = 0.21), or smoking habits
(26.67% vs. 25%; P = 0.91). Individuals from the carrier
group were more often on medication, treated with
neuroleptic or psychotropic drugs and/or drugs that pre-
vent cardiovascular diseases (46.67% vs. 15%; P = 0.048),
consistent with the literature [24,25].
Neurological assessment of the participants showed
that the FXTAS Rating Scale scores (evaluating move-
ment disorder symptoms) were low to normal (the high-
est score was 53 out of a maximum possible score of
329; Additional file 1: Table S1), emphasizing that all
subjects examined were asymptomatic and none of
them met the criteria for FXTAS diagnosis. Nonethe-
less, the scores were significantly higher in carriers,
when compared with controls (23.73 ± 10.40 vs. 12 ±
11.07; P = 0.003; Figure 1A), with three outliers – two
in the control group and one among the premutation
carriers. The boxplot also showed differences in median
between both groups (Figure 1B). Taking into consider-
ation that seven tests each at an α level of 5% were per-
formed to assess the group effect on the phenotypes,
only the P value (0.003) associated with the FXTAS rat-
ing score remained significant after Bonferroni correc-
tion, showing that the score means between the groups
could not be considered equal. In addition, multiple re-
gression analyses taking into account age and CGG re-
peat numbers explained 52.5% (R2) of the FXTAS scale
score, with P <0.0003 and P = 0.0014, respectively. Mul-
tiple regressions were also run taking into account
smoking status, DBP, SBP, and hemoglobin A1c; these
variables never appeared significant in any of the
analyses.
Presence of the FXTAS-causative mutation and the
number of CGG repeats correlate positively with IL-10
amounts in peripheral blood
A set of three cytokines (IL-6, IL-8, and IL-10) was ana-
lyzed. This choice was based on previous studies report-
ing inflammatory changes occurring in somewhat
similar neurodegenerative disorders, including AD, PD,
and HD [14,26]. The selected cytokines were measured
in the supernatants of PBMCs; measurements were car-
ried out in duplicate (for IL-10) or in triplicate (for IL-6
and IL-8). In order to evaluate the quality of the tech-
nical replicates, Pearson’s correlations of the repeated
Characteristics Mean +/- SD or % 
One-way 
Anova 
Kruskal-
Wallis test 
Generalized 
linear model 
regression 
Controls Premutation p-value 
Age (years) 45.70 +/- 11.36 52.20 +/- 11.60 0.11 NA NA 
DBP (mmHg) 78.35 +/- 8.95 83.15 +/- 7.12 NA 0.10 NA 
SBP (mmHg) 120.30 +/-12.74 124.36 +/- 11.74 NA 0.21 NA 
HbA1C (% total Hb) 5.42 +/- 0.50 5.86 +/- 1.50 NA 0.21 NA 
Smoking (%) 25 26.67 NA NA 0.91 
Drugs (%) 15 46.67 NA NA 0.048 
FXTAS score 12 +/- 11.07 23.73 +/- 10.40 0.003 NA NA 
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Figure 1 Effect of the FXTAS premutation status on the various phenotypes studied. (A) For each phenotype, the mean and standard
deviation (SD) (or the percentage) were computed for the control and premutation groups. Various statistical tests were applied and their
associated P values were computed according to the type and the distribution of the phenotypes in order to assess the effect of the clinical
status. For normally distributed features (age and Fragile X-associated tremor/ataxia syndrome (FXTAS) score), a one-way analysis of variance was
used. For the non-normally distributed phenotypes, such as diastolic and systolic blood pressure (DBP and SBP) and hemoglobin A1c (HbA1c)
concentrations, a Kruskal–Wallis test was applied using the ranks instead of the raw values. Finally, for binary phenotypes (percentage of smokers
and of individuals under treatment), a generalized linear model was applied. (B) Boxplot representing the distribution (median and interquartile
range) of the FXTAS scores for control and premutation groups.
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addition, the correlations between the averaged log-
transformed cytokine concentrations were estimated.
The correlations between the repeated measurements
were all above 0.85, suggesting the use of the average
concentrations as a reasonable choice for the modeling
analyses (Figure 2).
We observed a positive linear relationship between
the concentration of the anti-inflammatory cytokine IL-
10 and the number of CGG repeats (Figure 3A,B). The
number of CGG repeats was able to explain 24% (R2) of
the observed variations of the averaged log-transformed
IL-10 levels, with P = 0.002, which remained significant
after Bonferroni multiple testing correction (three tests
were considered). Multiple linear regressions modeling
of the cytokines’ concentrations as a function of the
CGG repeats and age did not indicate any significanteffect of age on any of the cytokines studied (Figure 4).
In addition, we observed no linear relationship between
medication and the levels of cytokines (data not shown).
Conversely, the CGG number was significantly corre-
lated with IL-10 concentrations (P = 0.0035; Figure 4).
We therefore further analyzed the group effect, as
shown in Figure 5A,B. A significant increase of IL-10
(P = 0.019) was observed in premutation carriers when
compared with controls. As all premutation carriers
included in this study are asymptomatic, this suggests
that the IL-10 variation is an early event occurring
prior to classical neurological symptoms.
The relationship between the level of cytokines and
FXTAS clinical scores was assessed by regression ana-
lysis. No correlation above 0.14 between any of the
cytokines and FXTAS scores was observed (data not
shown).
Log-cytokine beta se p-value R2
mIL-6 0.0063 0.0037 0.0982 0.0784 
mIL-8 0.0036 0.0022 0.1066 0.0748 
mIL-10 0.0100 0.0030 0.0021 0.2451 
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Figure 3 Effect of CGG repeat length on the mean cytokine concentrations. (A) Each log-transformed averaged cytokine basal
concentration was regressed on the number of CGG repeats. Results of the linear modeling include the beta coefficient, the standard error (se),
the Student’s t-test P value associated with the coefficient of the CGG variable and R2, the fraction of variance explained by the number of CGG
repeats. The highlighted results describe the cytokine (mIL-10) for which the number of CGG repeats is significantly associated after multiple
testing correction. (B) The regression plot represents the logarithm of the mean IL-10 basal concentration (in pg/ml) as the function of the CGG
repeats. Each mean value (average of the two repeated measures) is represented by a diamond, and the error bar corresponds to the mean ±
standard deviation. The regression line shows the fit of the data for which the equation of regression is also given.
Log-cytokine 
correlations  
mIL-6 mIL-8 mIL-10 
IL-6(1) IL-6(2) IL-6(3) IL-8(1) IL-8(2) IL-8(3) IL-10(1) IL-10(2) 
mIL-6 
IL-6(1) 1 
0.79 (10-8) 0.64 (10-5) IL-6(2) 0.95 (10-19) 
IL-6(3) 0.98 (10
-26) 0.97 (10-22) 
mIL-8 
IL-8(1) 1 
0.58 (10-4) IL-8(2) 0.92 (10-15) 
IL-8(3) 0.92 (10
-14) 0.87 (10-11) 
mIL-10 IL-10(1) 1 
IL-10(2) 0.98 (10
-21) 
Figure 2 Correlations between and within the log-transformed cytokine measurements. Table shows the correlation structure between
and within the log-transformed cytokine levels. The Pearson's correlations within a cytokine were computed using repeated measurements. For
each of the three cytokines, the mean value was computed based on the repeated measurements and then the correlation between the
averaged values was estimated (highlighted in grey). Numbers in brackets reflect the order of magnitude of the P values testing the hypothesis
of no correlation against the alternative that there is a non-zero correlation.
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CGG Age 
Log-cytokine beta se p-value beta se p-value R 2
mIL-6 0.0066 0.0039 0.0981 -0.0027 0.0086 0.7609 0.0810 
mIL-8 0.0035 0.0023 0.1310 0.0009 0.0051 0.8675 0.0756 
mIL-10 0.0099 0.0031 0.0035 0.0011 0.0070 0.8716 0.2457 
Figure 4 Effect of the CGG repeats number and age on the mean cytokine concentrations. Each log-transformed averaged cytokine basal
concentration was regressed on the number of CGG repeats and the age variables. Results of the linear modeling include the beta coefficients,
the standard errors (se), the Student’s t-test P values associated with the two coefficients (CGG repeats and age variables) and R2, the fraction of
variance explained by the two variables. The highlighted results describe the cytokine (mIL-10) for which the number of CGG repeats is
significantly associated after multiple testing correction.
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We measured the peripheral blood cytokines IL-6, IL-8,
and IL-10 in the carriers of the FMR1 premutation and
in control individuals, and found that carriers had
significantly higher levels of the anti-inflammatory
cytokine IL-10. Concentrations of IL-10 significantly
correlated with the number of CGG repeats, whereasMea
Controls 
mIL-10 (pg/mL) 7.16 +/- 0.15 
A 
B 
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Figure 5 Group effect on the mean IL-10 concentrations. (A) Mean and
concentrations for the control and premutation groups, as well as the P va
representing the distribution (median and interquartile range) of the meanthe concentrations of proinflammatory cytokines IL-6
and IL-8 did not.
IL-10 is a key orchestrator of the immune system with
potent anti-inflammatory effects. An increase in IL-10 con-
centration in the peripheral blood was previously demon-
strated in other neurodegenerative disorders, such as PD
and HD [26,27]. Although it is less severe, FXTAS sharesn +/- SD  One-way Anova 
Premutation p-value
7.57 +/- 0.09 0.019 
noitatumerP
standard deviation (SD) of the log-transformed averaged IL-10
lue associated with the one-way analysis of variance. (B) Boxplot
IL-10 concentrations for control and premutation groups.
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sions, the presence of intranuclear inclusions, abnormal
movements and cognitive decline. HD-specific trinucleo-
tide-repeat expansions are thought to primarily cause ac-
cumulation of the abnormal polyglutamine-containing
proteins [28], unlike FXTAS repeats that affect the 50-
UTR of FMR1 mRNA. It is tempting to speculate that an
accumulation of the expanded mRNA, which was also
reported in HD, plays a role in the activation of specific
immune pathways involved in these types of diseases.
In our study, we did not find a significant increase in
the concentration of proinflammatory cytokines IL-6 and
IL-8 in peripheral blood, as observed in the blood as well
as in the brain of patients affected by AD, PD, and HD
[29,30]. Bjorkqvist and colleagues compared plasma
levels of numerous cytokines in HD patients and
observed that the combination of plasma IL-6, IL-8, and
IL-10 levels could very efficiently differentiate between
HD expansion carriers (premanifest and manifest) and
controls [26]. We did not have symptomatic FXTAS
patients available for our analysis, and future studies
would be necessary to identify if and how the immune
status of these individuals changes in the presence of
symptoms. However, as shown in Figure 2, we do observe
a strong correlation between IL-6 and IL-8 concentra-
tions (r = 0.79), whereas the correlation with IL-10 con-
centrations is weaker (r = 0.64 and r = 0.58, respectively).
IL-10 is secreted by various cell types: different T-cell
subsets, macrophages, dendritic cells, B cells, mast cells,
and eosinophils [31-33]. The increased IL-10 levels
observed in FMR1 premutation carriers could therefore be
due to activation of immune cells, as well as a direct conse-
quence of IL-10 gene overexpression in PBMCs. Specific-
ally, the FMR1 gene is expressed in PBMCs [34]; therefore
the expression of the pathological repeats could alter in-
trinsic properties of PBMCs and lead to the increased IL-
10 production. In general, cells expressing FMR1 mRNA
containing more than 55 CGG repeats were shown to have
growth defects, abnormal distribution of lamin and
enhanced expression of stress proteins [4]; these could po-
tentially trigger an increase of IL-10 production in many
diverse immune cells. Further studies will be needed to
elucidate the precise mechanism of IL-10 production.
Deregulation of IL-10 was associated with various
diseases, such as cancer, rheumatoid arthritis, systemic
lupus erythematosus, asthma, infectious disorders, and
so forth [31], where both overexpression and IL-10
deficiency were shown to have a pathophysiological
significance. Most often enhanced expression of IL-10
is beneficial for the individuals due to the activation
of anti-inflammatory mechanisms, although a detri-
mental effect of IL-10 overexpression was demon-
strated in a mouse model that subsequently developed
a demyelinating peripheral neuropathy [35]. AlthoughFXTAS patients show a reduction of brain myelin con-
tent that is also associated with neuronal loss [1], it is
hard to say whether this is somehow related to the
observed increase of IL-10 levels in peripheral blood.
The relationship between increased concentrations of
IL-10 in the peripheral blood of FXTAS patients and
central nervous system pathology remains unknown.
Pathological changes in the nervous system and
increased IL-10 levels in peripheral blood could be inde-
pendent consequences of CGG-repeat expression in
these different compartments. Alternatively, inflamma-
tory activation may originate in the central nervous sys-
tem, with immunomodulators crossing the brain–blood
barrier and reaching the peripheral circulation.
Levels of IL-10 discriminate premutation carriers from
controls and may represent a valuable early biomarker.
The design of this study including asymptomatic young
carriers did not permit any correlation with the progres-
sion of the disease. Longitudinal studies including car-
riers affected with FXTAS are required to address this
question.
Additional file
Additional file 1: Table S1. Dataset used for the study. Presenting, for
the 35 subjects involved in this study, the clinical status, age, number of
CGG repeats, cytokine measurements (IL-6, IL-8 and IL-10), relevant
clinical scores (CRST, UPDRS, ICARS and FXTAS), as well as additional
clinical features: diabetes status, smoking status, DBP, SBP, C-reactive
protein (CRP) levels, percentage of glycated hemoglobin (HbA1c),
treatment status, and the number of psychotropic drugs and pro-tremor/
ataxia treatments.
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